We are live on ! Find out more

Ascentage Pharma

AAPG

Market cap $1.4B

15.00 USD

-0.50

3.23%

At close Updated Nov 11, 4:00 PM EST

1 day

-3.23%

5 days

-0.86%

1 month

-2.02%

3 months

-20.97%

6 months

-30.75%

Year to date

-43.12%

1 year

-53.18%

5 years

-13.69%

10 years

-13.69%

About: Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

Employees: 828

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 72.7%

Negative 0%

Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026

ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that multiple clinical and preclinical studies have been selected at the 68th American Society of Hematology (ASH) Annual Meeting, involving four of the Company's proprietary innovative drug candidates, namely olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China, lisaftoclax (APG-2575), a potentially best-in-class Bcl-2 inhibitor approved in China, APG-5918, a PRC2/EED inhibitor, and APG-3288, a BTK protein degrader. These new data presentations highlight the Company's global innovation capabilities in hematologic malignancies. Notably, APG-5918 was selected for an oral presentation upon the first disclosure of its clinical data.

Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London

ROCKVILLE, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in two upcoming investor conferences in London, United Kingdom.

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London

Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company's novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), in combination with acalabrutinib, for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

Ascentage Pharma Stock Could More Than Double: Analyst

Ascentage Pharma Group International (NASDAQ:AAPG) stock could see significant upside as the cancer drug developer approaches several major clinical trial results in 2027, according to William Blair.

Ascentage Pharma Stock Could More Than Double: Analyst

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been looking beyond the Magnificent Seven for growth opportunities, and smaller companies with improving fundamentals, unique business models, or other noteworthy catalysts may finally have an opportunity to win investor attention.

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in four upcoming investor conferences in New York, New York.

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript

Ascentage Pharma Group International H1 Earnings Call Highlights

Ascentage Pharma Group International NASDAQ: AAPG reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside China.

Ascentage Pharma Group International H1 Earnings Call Highlights

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr.

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

See News Rankings

Price charts implemented using Lightweight Charts™